title: [Coronary disease risk and prevalence of heart disease in primary care patients with hypertension and renal disease].
abstract: OBJECTIVE
  The presence of renal disease significantly alters the cardiovascular risk of patients with high blood pressure. However, few studies have examined renal parameters in primary care patients. The objectives of this study were to investigate cardiovascular risk and the factors influencing it in hypertensive patients with renal disease and to compare the findings with those in hypertensive patients without renal disease.
  
  
  METHODS
  The CORONARIA study involved primary care patients with hypertension from all regions of Spain and included two groups with different degrees of renal disease.
  
  
  RESULTS
  In total, 703 patients (9.8%) had renal disease. Hypertensive patients with renal disease had a worse cardiovascular risk profile than other hypertensives. The prevalence of diabetes was double in patients with renal disease. Moreover, the risk of a coronary event was significantly higher in those with renal disease. One-third of hypertensives with renal disease had another previously diagnosed cardiovascular disease. In addition, they more frequently had a history of angina, were twice as likely to have had a myocardial infarction, and were more than twice as likely to have undergone revascularization or to have peripheral vascular disease or cerebrovascular disease. Heart failure was four times more frequent in these patients with renal disease than in other hypertensives.
  
  
  CONCLUSIONS
  Patients with hypertension and renal disease have a higher risk of cardiovascular disease, exhibit an increased prevalence of diabetes, and suffer from more extensive target organ damage.
authors.affiliation: Unidad de Cardiocirculatorio, Centro de investigación Hospital La Fe, Valencia, Spain. hernandiz_amp@gva.es
authors.forename: Juan
authors.initials: J
authors.lastname: Cosín-Aguilar
authors.forename: Amparo
authors.initials: A
authors.lastname: Hernándiz-Martínez
authors.forename: Rosa
authors.initials: R
authors.lastname: Arístegui-Urrestarazu
authors.forename: Xavier
authors.initials: X
authors.lastname: Masramón-Morell
authors.forename: Amparo
authors.initials: A
authors.lastname: Aguilar-Llopis
authors.forename: Luís
authors.initials: L
authors.lastname: Rodríguez-Padial
authors.forename: José L
authors.initials: JL
authors.lastname: Zamorano-Gómez
mesh_terms: D000328:Adult; D000367:Age Factors; D000368:Aged; D017311:Amlodipine / Q000008:administration & dosage / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000453:epidemiology* / Q000209:etiology / Q000517:prevention & control; D003920:Diabetes Mellitus / Q000453:epidemiology; D005260:Female; D006331:Heart Diseases / Q000453:epidemiology*; D006333:Heart Failure / Q000453:epidemiology; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy; D007674:Kidney Diseases / Q000150:complications*; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011320:Primary Health Care; D011322:Primary Prevention; D012307:Risk Factors; D013030:Spain / Q000453:epidemiology; D013997:Time Factors
chemical_list: D000959:Antihypertensive Agents; D017311:Amlodipine